Andere Sprachen Syros Pharmaceuticals, Inc.

Aktien

A3DT8V

US87184Q2066

SYRS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
5,2 ^USD	-4,41 %		+1,96 %	-33,25 %

09.04.	Sektor-Update: Aktien des Gesundheitswesens am späten Nachmittag uneinheitlich	MT
09.04.	Syros erhält Fast Track Label für Tamibarotene zur Behandlung von akuter myeloischer Leukämie; Aktien steigen	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09.04.
Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise	09.04.
Syros Gets FDA Fast-Track Designation for Tamibarotene	09.04.
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09.04.
Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression	09.04.
Syros Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03.04.
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02.04.
Health Care Rises as Upward Momentum Builds -- Health Care Roundup	28.03.
Health Care Jumps as Upward Momentum Builds -- Health Care Roundup	27.03.
Earnings Flash (SYRS) SYROS PHARMACEUTICALS Reports Q4 Revenue $387,000	27.03.
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update	27.03.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.03.
Syros Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
North American Morning Briefing : Stocks Edge -2-	27.03.
Syros Pharmaceuticals Completes Enrollment of 190 People in Phase 3 Trial of Tamibarotene	25.03.
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial	25.03.
Syros Pharmaceuticals Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in Select-MDS-1 Phase 3 Trial	25.03.
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024	20.03.
Syros to Participate in TD Cowen 44th Annual Health Care Conference	27.02.
Thinking about buying stock in Applied UV, Crowdstrike, Syros Pharmaceuticals, Captivision, or Polestar Automotive?	01.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Syros Pharmaceuticals, Inc.

Aktien

A3DT8V

US87184Q2066

SYRS

Andere Sprachen

Filter